Fabienne Douce-Piras
Marcy, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Safety and immunogenicity of a cytomegalovirus (CMV) recombinant glycoprotein B (gB) vaccine in combination with polyacrylate or an emulsion-based adjuvants.
Journal: Vaccine
Published: January 10, 2026
Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
Journal: Journal of virology
Published: April 03, 2024
Development of Mass Spectrometry Imaging on skeletal muscle to characterize the local pro-inflammatory and pro-resolution lipid responses in a vaccination context.
Journal: Journal of proteomics
Published: October 31, 2023
Genetic and Functional Characterization of Congenital HCMV Clinical Strains in Ex Vivo First Trimester Placental Model.
Journal: Pathogens (Basel, Switzerland)
Published: April 15, 2023
Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant.
Journal: Toxicology and applied pharmacology
Published: November 03, 2022
A potent novel vaccine adjuvant based on straight polyacrylate.
Journal: International journal of pharmaceutics: X
Published: May 21, 2020
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Journal: EBioMedicine
Published: July 16, 2019
Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Journal: The Journal of infectious diseases
Published: October 16, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026